Health Care & Life Sciences » Biotechnology | Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
-
-
799.00
35,376.80
33,586
Cost of Goods Sold (COGS) incl. D&A
10.40
38.30
67.90
-
-
-
Gross Income
10.40
38.30
67.90
-
-
-
SG&A Expense
11,587.80
22,249.90
24,062.80
30,525.00
52,819.00
51,772
EBIT
11,598.30
22,288.20
24,130.70
29,831.80
17,550.50
18,277
Unusual Expense
3,457.20
-
-
-
-
-
Non Operating Income/Expense
120.60
19.30
15.80
29.90
75.70
1
Interest Expense
462.60
70.00
70.00
70.00
662.40
696
Pretax Income
15,616.50
22,319.90
24,148.60
29,733.40
17,396.40
18,010
Consolidated Net Income
4,600.00
22,319.90
24,148.60
29,733.40
17,396.40
18,010
Net Income
4,600.00
22,319.90
24,148.60
29,733.40
17,396.40
18,010
Net Income After Extraordinaries
4,600.00
22,319.90
24,148.60
29,733.40
17,396.40
18,010
Net Income Available to Common
4,600.00
22,319.90
24,148.60
29,733.40
17,396.40
18,010
EPS (Basic)
0.63
1.44
1.30
1.31
0.61
0.59
Basic Shares Outstanding
7,358.20
15,479.00
18,617.50
22,649.90
28,586.60
30,370
EPS (Diluted)
0.63
1.44
1.30
1.31
0.61
0.59
Diluted Shares Outstanding
7,358.20
15,479.00
18,617.50
22,649.90
28,586.60
30,370
EBITDA
11,587.80
22,249.90
24,062.80
29,725.90
17,442.20
18,186
Non-Operating Interest Income
22.10
57.60
67.90
138.40
892.20
962
Other After Tax Income (Expense)
11,016.50
-
-
-
-
-

About Conatus Pharmaceuticals

View Profile
Address
16745 West Bernardo Drive
San Diego California 92127
United States
Employees -
Website http://www.conatuspharma.com
Updated 07/08/2019
Conatus Pharmaceuticals, Inc. engages in the development and commercialization of medicines for the treatment of liver diseases. It focuses in development of emricasan, an active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease, which reduce the activities of human caspases. The company was founded by Alfred P.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.